Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
Atkinson V, Sandhu S, Hospers G, Long GV, Aglietta M, Ferrucci PF, Tulyte S, Cappellini GCA, Soriano V, Ali S, Poprach A, Cesas A, Rodriguez-Abreu D, Lau M, de Jong E, Legenne P, Stein D, King B, van Thienen JV. Atkinson V, et al. Among authors: ali s. Melanoma Res. 2020 Jun;30(3):261-267. doi: 10.1097/CMR.0000000000000654. Melanoma Res. 2020. PMID: 31895752
Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma.
Mason R, Dearden HC, Nguyen B, Soon JA, Smith JL, Randhawa M, Mant A, Warburton L, Lo S, Meniawy T, Guminski A, Parente P, Ali S, Haydon A, Long GV, Carlino MS, Millward M, Atkinson VG, Menzies AM. Mason R, et al. Among authors: ali s. Pigment Cell Melanoma Res. 2020 Mar;33(2):358-365. doi: 10.1111/pcmr.12831. Epub 2019 Nov 2. Pigment Cell Melanoma Res. 2020. PMID: 31587511
G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma.
Kelly GM, Al-Ejeh F, McCuaig R, Casciello F, Ahmad Kamal N, Ferguson B, Pritchard AL, Ali S, Silva IP, Wilmott JS, Long GV, Scolyer RA, Rao S, Hayward NK, Gannon F, Lee JS. Kelly GM, et al. Among authors: ali s. Clin Cancer Res. 2021 May 1;27(9):2624-2635. doi: 10.1158/1078-0432.CCR-20-3463. Epub 2021 Feb 15. Clin Cancer Res. 2021. PMID: 33589432
Selective Targeting of Protein Kinase C (PKC)-θ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8+ T Cells in Immunotherapy-Resistant and Metastatic Cancers.
Dunn J, McCuaig RD, Tan AHY, Tu WJ, Wu F, Wagstaff KM, Zafar A, Ali S, Diwakar H, Dahlstrom JE, Bean EG, Forwood JK, Tsimbalyuk S, Cross EM, Hardy K, Bain AL, Ahern E, Dolcetti R, Mazzieri R, Yip D, Eastgate M, Malik L, Milburn P, Jans DA, Rao S. Dunn J, et al. Among authors: ali s. Cancers (Basel). 2022 Mar 21;14(6):1596. doi: 10.3390/cancers14061596. Cancers (Basel). 2022. PMID: 35326747 Free PMC article.
Metformin in prostate cancer: two for the price of one.
Clements A, Gao B, Yeap SHO, Wong MKY, Ali SS, Gurney H. Clements A, et al. Among authors: ali ss. Ann Oncol. 2011 Dec;22(12):2556-2560. doi: 10.1093/annonc/mdr037. Epub 2011 Mar 18. Ann Oncol. 2011. PMID: 21421541 Free article. Review.
13,208 results
You have reached the last available page of results. Please see the User Guide for more information.